Friday, June 09, 2017 2:47:28 PM
My transcription:
"The drug trial plan is very rational and will try to be addressing the goal to get the drug to market and after the p1 we did the p2a which was on purpose a informative trial to learn as much as possible with a focus on population from the genetics. We so far have disclosed -or a- presented part a and part b of the trial and the population for genetic analysis and the respective actionable correlation data will be forthcoming. With that data we will then be able to design more narrowly and more specifically the Phase 2 study in Rett and Parkinson's as well as Alzheimer's which we are initiating this year."
Note that genetic data from P2 AZ seems to have a bearing on the Rett and Parkinson's trial.
In Peace, In War
Recent AVXL News
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
